Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.75 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.75 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.75 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | DPP4 | P27487 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.75 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.75 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.75 |
| ▸ | GAPDH | P04406 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | STAT6 | P42226 | 1/20 | 0.75 |
| ▸ | PI4KA | P42356 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.75 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.75 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.75 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.75 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL3183004 | 0.99 | ADORA1 (0.77) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL2442774 | 0.99 | ADORA1 (0.77) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL3166848 | 0.98 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL924728 | 0.98 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL3134331 | 0.98 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL7516483 | 0.98 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL3343948 | 0.98 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL925631 | 0.98 | ADORA1 (0.75) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL3332132 | 0.97 | ADORA1 (0.74) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL10396858 | 0.97 | ADORA1 (0.74) | ADORA1SMN1; SMN2DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332583-B1 | ANTIVIRAL DISINFECTANTS AND THEIR APPLICATIONS | GOJO IND INC (US) | 2018-12-19 | — | — | EP | claimed |
| US-20130237598-A1 | ANTIVIRAL COMPOSITIONS | GOJO INDUSTRIES, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-8450378-B2 | Antiviral method | GOJO INDUSTRIES, INC. (US) | 2013-05-28 | — | — | US | claimed |
| US-20120171156-A1 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LTD. (GB) | 2012-07-05 | — | — | US | claimed |
| EP-2442873-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | Hds Limited (GB) | 2012-04-25 | — | — | EP | claimed |
| WO-2010146142-A9 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2011-06-16 | — | — | WO | claimed |
| EP-2332583-A1 | Antiviral disinfectants and their applications | Gojo Industries, Inc. (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010146142-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2010-12-23 | — | — | WO | claimed |
| US-20090018213-A1 | ANTIVIRAL METHOD | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2009-01-15 | — | — | US | claimed |
| US-20060127430-A1 | Controlled-Release of Cosmetic and Pharmaceutical Agents via Osmotic Nano-Diffusion from Zeolite Cage Complexes | BIODERM RESEARCH (US) | 2006-06-15 | — | — | US | claimed |
| WO-2026104886-A1 | METHOD FOR EXTRACTING LOW-MOLECULAR WEIGHT COLLAGEN USING POLLACK SKIN, LOW-MOLECULAR WEIGHT COLLAGEN, AND COSMETIC COMPOSITION COMPRISING SAME WITH SKIN REGENERATION EFFICACY | 유엔케이코리아 주식회사 | 2026-05-21 | — | — | WO | disclosed |
| US-12350352-B2 | Composition for surface modification | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| EP-4464307-A1 | COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME | MPLUS COSMETICS S.R.L. (IT) | 2024-11-20 | — | — | EP | disclosed |
| US-20240374498-A1 | COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME | MPLUS COSMETICS S.R.L. (IT) | 2024-11-14 | — | — | US | disclosed |
| EP-3342395-B1 | COMPOSITION FOR HAIR SURFACE MODIFICATION | LG HOUSEHOLD & HEALTH CARE LTD (KR) | 2024-08-07 | — | — | EP | disclosed |
| US-20070185216-A1 | ANTIVIRAL METHOD | PNC BANK, NATIONAL ASSOCIATION, AS AGENT | 2007-08-09 | — | — | US | disclosed |
| US-20070166255-A1 | Treatment of Topical Discomforts Including Acne, Sunburn, Diaper Rash, Wound, Wrinkles and Dandruff/Hair Loss by Natural Lignans via Fatty Acid Desaturase Inhibition | GUPTA SHYAM K | 2007-07-19 | — | — | US | disclosed |
| US-20060183708-A1 | Topical Delivery of Trace Metals for Enzyme Modulation | BIODERM RESEARCH (US) | 2006-08-17 | — | — | US | disclosed |
| US-20060110415-A1 | Topical Delivery System for Cosmetic and Pharmaceutical Agents | BIODERM RESEARCH (US) | 2006-05-25 | — | — | US | disclosed |
| US-20050175556-A1 | Skin Darkening (Sunless Tanning) Compositions Based on Enhancement of Melanin Synthesis by Tyrosinase Promoters | BIODERM RESEARCH (US) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350352-B2 | Composition for surface modification | CUTA, PTMS, DNMT1 | ADORA1 3913/4885ADORA3 3249/4885ADORA2A 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.